Latest News
ArriVent BioPharma, Inc.
- ArriVent’s Firmonertinib Phase 1b Data Published in Cancer Cell
- ArriVent doses first patient with ARR-002 dual-target ADC for ovarian cancer
- Fierce Pharma Asia—Novartis’ $7.8B mRNA deal; Shionogi’s $2B buy; ArriVent’s phase 3 flop
- Form 13D/A ArriVent BioPharma For: 8 October By Investing.com
- AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
- AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
- Chinese biotech faces reality check as ArriVent drug failure sinks stock in US
- ArriVent sheds nearly half of value on late-stage lung cancer miss
- ArriVent’s stock plummets on Phase III NSCLC trial failure
- ArriVent’s phase 3 lung cancer trial flops, sinking stock
- ArriVent collapses on disappointing lung cancer data
- Why is Arrivent Biopharma stock collapsing today?
Headlines from the last 30 days, linking to the original publishers. See all market news →